This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Handman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Handman, E.

Next Article 

Clinical Microbiology Reviews, April 2001, p. 229-243, Vol. 14, No. 2
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.2.229-243.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Leishmaniasis: Current Status of Vaccine Development

Emanuela Handman*

Infection and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Parkville 3050, Australia

Leishmaniae are obligatory intracellular protozoa in mononuclear phagocytes. They cause a spectrum of diseases, ranging in severity from spontaneously healing skin lesions to fatal visceral disease. Worldwide, there are 2 million new cases each year and 1/10 of the world's population is at risk of infection. To date, there are no vaccines against leishmaniasis and control measures rely on chemotherapy to alleviate disease and on vector control to reduce transmission. However, a major vaccine development program aimed initially at cutaneous leishmaniasis is under way. Studies in animal models and humans are evaluating the potential of genetically modified live attenuated vaccines, as well as a variety of recombinant antigens or the DNA encoding them. The program also focuses on new adjuvants, including cytokines, and delivery systems to target the T helper type 1 immune responses required for the elimination of this intracellular organism. The availability, in the near future, of the DNA sequences of the human and Leishmania genomes will extend the vaccine program. New vaccine candidates such as parasite virulence factors will be identified. Host susceptibility genes will be mapped to allow the vaccine to be targeted to the population most in need of protection.

* Mailing address: Infection and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, The Royal Melbourne Hospital, Parkville 3050, Australia. Phone: 61-3-9345 2555. Fax: 61-3-9347 0852. E-mail: handman{at}wehi.edu.au.

Clinical Microbiology Reviews, April 2001, p. 229-243, Vol. 14, No. 2
0893-8512/01/$04.00+0   DOI: 10.1128/CMR.14.2.229-243.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Serrano-Martin, X., Garcia-Marchan, Y., Fernandez, A., Rodriguez, N., Rojas, H., Visbal, G., Benaim, G. (2009). Amiodarone Destabilizes Intracellular Ca2+ Homeostasis and Biosynthesis of Sterols in Leishmania mexicana. Antimicrob. Agents Chemother. 53: 1403-1410 [Abstract] [Full Text]  
  • Dunning, N. (2009). Leishmania vaccines: from leishmanization to the era of DNA technology. Bioscience Horizons 2: 73-82 [Abstract] [Full Text]  
  • Whitaker, S. M., Colmenares, M., Pestana, K. G., McMahon-Pratt, D. (2008). Leishmania pifanoi Proteoglycolipid Complex P8 Induces Macrophage Cytokine Production through Toll-Like Receptor 4. Infect. Immun. 76: 2149-2156 [Abstract] [Full Text]  
  • Bhowmick, S., Ravindran, R., Ali, N. (2008). gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani. Infect. Immun. 76: 1003-1015 [Abstract] [Full Text]  
  • Silvestre, R., Cordeiro-Da-Silva, A., Santarem, N., Vergnes, B., Sereno, D., Ouaissi, A. (2007). SIR2-Deficient Leishmania infantum Induces a Defined IFN-{gamma}/IL-10 Pattern That Correlates with Protection. J. Immunol. 179: 3161-3170 [Abstract] [Full Text]  
  • Dutta, A., Bandyopadhyay, S., Mandal, C., Chatterjee, M. (2007). Aloe vera leaf exudate induces a caspase-independent cell death in Leishmania donovani promastigotes. J Med Microbiol 56: 629-636 [Abstract] [Full Text]  
  • Joshi, M. B., Dwyer, D. M. (2007). Molecular and Functional Analyses of a Novel Class I Secretory Nuclease from the Human Pathogen, Leishmania donovani. J. Biol. Chem. 282: 10079-10095 [Abstract] [Full Text]  
  • GALINDO-SEVILLA, N., SOTO, N., MANCILLA, J., CERBULO, A., ZAMBRANO, E., CHAVIRA, R., HUERTO, J. (2007). LOW SERUM LEVELS OF DEHYDROEPIANDROSTERONE AND CORTISOL IN HUMAN DIFFUSE CUTANEOUS LEISHMANIASIS BY LEISHMANIA MEXICANA. Am J Trop Med Hyg 76: 566-572 [Abstract] [Full Text]  
  • TONUI, W. K., TITUS, R. G. (2007). CROSS-PROTECTION AGAINST LEISHMANIA DONOVANI BUT NOT L. BRAZILIENSIS CAUSED BY VACCINATION WITH L. MAJOR SOLUBLE PROMASTIGOTE EXOGENOUS ANTIGENS IN BALB/C MICE. Am J Trop Med Hyg 76: 579-584 [Abstract] [Full Text]  
  • Piscopo, T. V, Mallia Azzopardi, C. (2007). Leishmaniasis.. Postgrad. Med. J. 83: 649-657 [Abstract] [Full Text]  
  • Piscopo, T V, Mallia, A C (2006). Leishmaniasis.. Postgrad. Med. J. 82: 649-657 [Abstract] [Full Text]  
  • Pilatz, S., Breitbach, K., Hein, N., Fehlhaber, B., Schulze, J., Brenneke, B., Eberl, L., Steinmetz, I. (2006). Identification of Burkholderia pseudomallei Genes Required for the Intracellular Life Cycle and In Vivo Virulence.. Infect. Immun. 74: 3576-3586 [Abstract] [Full Text]  
  • Rama Iniguez, S., Dea-Ayuela, M. A., Sanchez-Brunete, J. A., Torrado, J. J., Alunda, J. M., Bolas-Fernandez, F. (2006). Real-Time Reverse Transcription-PCR Quantification of Cytokine mRNA Expression in Golden Syrian Hamster Infected with Leishmania infantum and Treated with a New Amphotericin B Formulation.. Antimicrob. Agents Chemother. 50: 1195-1201 [Abstract] [Full Text]  
  • Breton, M., Tremblay, M. J, Ouellette, M., Papadopoulou, B. (2005). Live Nonpathogenic Parasitic Vector as a Candidate Vaccine against Visceral Leishmaniasis. Infect. Immun. 73: 6372-6382 [Abstract] [Full Text]  
  • Iborra, S., Carrion, J., Anderson, C., Alonso, C., Sacks, D., Soto, M. (2005). Vaccination with the Leishmania infantum Acidic Ribosomal P0 Protein plus CpG Oligodeoxynucleotides Induces Protection against Cutaneous Leishmaniasis in C57BL/6 Mice but Does Not Prevent Progressive Disease in BALB/c Mice. Infect. Immun. 73: 5842-5852 [Abstract] [Full Text]  
  • Tabbara, K. S., Peters, N. C., Afrin, F., Mendez, S., Bertholet, S., Belkaid, Y., Sacks, D. L. (2005). Conditions Influencing the Efficacy of Vaccination with Live Organisms against Leishmania major Infection. Infect. Immun. 73: 4714-4722 [Abstract] [Full Text]  
  • Selvapandiyan, A., Stabler, K., Ansari, N. A., Kerby, S., Riemenschneider, J., Salotra, P., Duncan, R., Nakhasi, H. L. (2005). A Novel Semiquantitative Fluorescence-Based Multiplex Polymerase Chain Reaction Assay for Rapid Simultaneous Detection of Bacterial and Parasitic Pathogens from Blood. J. Mol. Diagn. 7: 268-275 [Abstract] [Full Text]  
  • Joshi, M. B., Rogers, M. E., Shakarian, A. M., Yamage, M., Al-Harthi, S. A., Bates, P. A., Dwyer, D. M. (2005). Molecular Characterization, Expression, and in Vivo Analysis of LmexCht1: THE CHITINASE OF THE HUMAN PATHOGEN, LEISHMANIA MEXICANA. J. Biol. Chem. 280: 3847-3861 [Abstract] [Full Text]  
  • ROGERS, K. A., TITUS, R. G. (2004). CHARACTERIZATION OF THE EARLY CELLULAR IMMUNE RESPONSE TO LEISHMANIA MAJOR USING PERIPHERAL BLOOD MONONUCLEAR CELLS FROM LEISHMANIA-NAIVE HUMANS. Am J Trop Med Hyg 71: 568-576 [Abstract] [Full Text]  
  • Tonui, W. K., Mejia, J. S., Hochberg, L., Mbow, M. L., Ryan, J. R., Chan, A. S. T., Martin, S. K., Titus, R. G. (2004). Immunization with Leishmania major Exogenous Antigens Protects Susceptible BALB/c Mice against Challenge Infection with L. major. Infect. Immun. 72: 5654-5661 [Abstract] [Full Text]  
  • Antoniazi, S., Price, H. P., Kropf, P., Freudenberg, M. A., Galanos, C., Smith, D. F., Muller, I. (2004). Chemokine Gene Expression in Toll-Like Receptor-Competent and -Deficient Mice Infected with Leishmania major. Infect. Immun. 72: 5168-5174 [Abstract] [Full Text]  
  • Pinto, E. F., Pinheiro, R. O., Rayol, A., Larraga, V., Rossi-Bergmann, B. (2004). Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACK. Infect. Immun. 72: 4521-4527 [Abstract] [Full Text]  
  • Selvapandiyan, A., Debrabant, A., Duncan, R., Muller, J., Salotra, P., Sreenivas, G., Salisbury, J. L., Nakhasi, H. L. (2004). Centrin Gene Disruption Impairs Stage-specific Basal Body Duplication and Cell Cycle Progression in Leishmania. J. Biol. Chem. 279: 25703-25710 [Abstract] [Full Text]  
  • Maes, L., Berghe, D. V., Germonprez, N., Quirijnen, L., Cos, P., De Kimpe, N., Van Puyvelde, L. (2004). In Vitro and In Vivo Activities of a Triterpenoid Saponin Extract (PX-6518) from the Plant Maesa balansae against Visceral Leishmania Species. Antimicrob. Agents Chemother. 48: 130-136 [Abstract] [Full Text]  
  • Sutherst, R. W. (2004). Global Change and Human Vulnerability to Vector-Borne Diseases. Clin. Microbiol. Rev. 17: 136-173 [Abstract] [Full Text]  
  • Kapotsis, G.E., Daniil, Z., Sardelis, Z., Stavrakaki, K., Saroglou, G., Pappa, V., Roussos, C., Papiris, S.A. (2004). Fever, rigors and sweats in an immunocompromised male. Eur Respir J 23: 176-178 [Full Text]  
  • Baldwin, T. M., Elso, C., Curtis, J., Buckingham, L., Handman, E. (2003). The Site of Leishmania major Infection Determines Disease Severity and Immune Responses. Infect. Immun. 71: 6830-6834 [Abstract] [Full Text]  
  • Iborra, S., Soto, M., Carrion, J., Nieto, A., Fernandez, E., Alonso, C., Requena, J. M. (2003). The Leishmania infantum Acidic Ribosomal Protein P0 Administered as a DNA Vaccine Confers Protective Immunity to Leishmania major Infection in BALB/c Mice. Infect. Immun. 71: 6562-6572 [Abstract] [Full Text]  
  • Davies, C. R, Kaye, P., Croft, S. L, Sundar, S. (2003). Leishmaniasis: new approaches to disease control. BMJ 326: 377-382 [Full Text]  
  • Padilla, A., Noiva, R., Lee, N., Mohan, K. V. K., Nakhasi, H. L., Debrabant, A. (2003). An Atypical Protein Disulfide Isomerase from the Protozoan Parasite Leishmania Containing a Single Thioredoxin-like Domain. J. Biol. Chem. 278: 1872-1878 [Abstract] [Full Text]  
  • Murray, H. W. (2002). Kala-Azar -- Progress against a Neglected Disease. NEJM 347: 1793-1794 [Full Text]  
  • Morty, R. E., Morehead, J. (2002). Cloning and Characterization of a Leucyl Aminopeptidase from Three Pathogenic Leishmania Species. J. Biol. Chem. 277: 26057-26065 [Abstract] [Full Text]  
  • Nicolas, L., Prina, E., Lang, T., Milon, G. (2002). Real-Time PCR for Detection and Quantitation of Leishmania in Mouse Tissues. J. Clin. Microbiol. 40: 1666-1669 [Abstract] [Full Text]  
  • Verthelyi, D., Kenney, R. T., Seder, R. A., Gam, A. A., Friedag, B., Klinman, D. M. (2002). CpG Oligodeoxynucleotides as Vaccine Adjuvants in Primates. J. Immunol. 168: 1659-1663 [Abstract] [Full Text]  
  • Papadopoulou, B., Roy, G., Breton, M., Kundig, C., Dumas, C., Fillion, I., Singh, A. K., Olivier, M., Ouellette, M. (2002). Reduced Infectivity of a Leishmania donovani Biopterin Transporter Genetic Mutant and Its Use as an Attenuated Strain for Vaccination. Infect. Immun. 70: 62-68 [Abstract] [Full Text]  
  • Selvapandiyan, A., Duncan, R., Debrabant, A., Bertholet, S., Sreenivas, G., Negi, N. S., Salotra, P., Nakhasi, H. L. (2001). Expression of a Mutant Form of Leishmania donovani Centrin Reduces the Growth of the Parasite. J. Biol. Chem. 276: 43253-43261 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»